Cipla Share Price, Stock Analysis & Company Profile

Cipla is one of India’s most established pharmaceutical companies, engaged in the development, manufacturing, and distribution of a broad range of branded generics, respiratory therapies, APIs, and consumer healthcare products. With decades of trust in domestic and international healthcare markets, the company remains a significant player in affordable medicine delivery.

Stay updated with broader pharmaceutical sector movements and compare Cipla with other leading healthcare stocks. Check the latest stock market insights here.

This page serves as a comprehensive resource for investors to track the Cipla share price on the NSE and BSE, along with essential data required for a detailed stock analysis.

About Cipla

Founded in 1935 by Khwaja Abdul Hamied, Cipla is headquartered in Mumbai, Maharashtra. The company has a long-standing legacy in the Indian pharmaceutical industry and is globally recognised for making life-saving medicines accessible at affordable prices.

Cipla has built strong capabilities across respiratory, anti-retroviral, urology, cardiology, and anti-infective therapies. Apart from India, the company has a strong presence in South Africa, the United States, Europe, and other emerging markets. Its diversified product portfolio, continuous innovation, and focus on chronic therapies have supported stable long-term growth.

The company also remains closely watched within the domestic pharma basket for its export momentum, margin profile, and regulated market opportunities. Investors looking to assess broader peer performance can also review the pharmaceutical industry landscape here

Cipla Business Model

Cipla operates through a diversified pharmaceutical business model:

• Domestic Formulations: A major portion of Cipla’s revenue comes from branded prescription medicines sold across India through a strong doctor-led and distribution-driven network

• Respiratory and Chronic Therapies: The company has a leadership position in respiratory care products and also generates significant sales from chronic treatment categories such as cardiac, diabetes, and urology.

• International Generics: Cipla exports generic medicines to regulated and semi-regulated markets, including the US, South Africa, and Europe, which supports foreign revenue diversification.

• Active Pharmaceutical Ingredients: The company manufactures APIs for captive use as well as commercial sale, helping maintain cost efficiency and supply chain reliability.

• Consumer Health Products: Cipla has expanded into wellness and over-the-counter healthcare through personal care and nutrition products, adding non-prescription revenue streams.

Cipla Listing and IPO Details

Cipla is listed on major Indian stock exchanges and is widely tracked among large-cap pharmaceutical sector stocks.

• NSE Symbol: CIPLA
   
• BSE Scrip Code: 500087
   
• Face Value: Rs 2 per share
   
• ISIN: INE059A01026

Sector Status:

 Cipla operates within the pharmaceuticals and drugs segment and is often analysed for its chronic therapy leadership, export performance, and consistent margin delivery.

Interested in upcoming healthcare IPOs and new listed opportunities in the pharma space, review the latest IPO and details here.

Cipla Corporate Action History

Cipla has maintained a shareholder-friendly capital allocation policy while continuing to invest in growth and research.

Stock Split History

The company has maintained a stable equity structure and has not frequently undertaken stock splits in recent years.

Dividend History

Cipla has a regular dividend payout track record supported by healthy cash generation and strong profitability.

• FY 2023-24: Declared a stable dividend reflecting consistent earnings growth and resilient domestic business.
   
• FY 2022-23: Continued dividend payouts despite global pricing pressure in certain export markets.

Note: Dividend declarations are influenced by profitability, cash reserves, and future expansion requirements.

Investor Resources Available on This Page

On this page, investors can access key financial and operational data for a structured Cipla stock analysis:

Price Chart: Track the latest trends and historical performance of the Cipla share price.

• Company Ratios: Evaluate important metrics such as Return on Equity (ROE), EBITDA margin, earnings growth, and return on capital employed.
  Want to compare Cipla with other pharma majors using valuation and profitability metrics, filter and analyse stocks using the advanced screener tool.
   
• Quarterly Results: Analyse revenue momentum, net profit trends, export contribution, and margin performance across key geographies.
   
• Balance Sheet & Cash Flow: Review debt levels, reserves, cash generation strength, and capital expenditure efficiency.
   
• Shareholding Pattern: Track promoter stake, FII participation, DII holdings, and retail investor movement.
   
• Pros & Cons: Quick insights into strengths such as chronic therapy leadership and strong brand equity versus risks like US pricing pressure and regulatory dependency.
  Looking for ready-made stock portfolios based on expert strategies, discover curated investment bundles tailored to different goals.
   
• Annual Reports: Download official annual reports and investor disclosures directly from the Reports Section on this page.

Build a deeper understanding of investing strategies and stock evaluation techniques, access curated investor resources and insights here.

Frequently Asked Questions

Q1. What is the latest Cipla share price?
The current share price is displayed at the top of this page. Data from NSE and BSE may be delayed by up to 15 minutes.

Q2. What does Cipla do?
Cipla is a pharmaceutical company engaged in branded generics, respiratory therapies, APIs, wellness products, and international generic exports.

Q3. Does Cipla pay dividends?
Yes, Cipla has a consistent dividend payout history backed by stable profitability and healthy cash reserves.

Q4. What is the face value of Cipla shares?
The face value of each equity share is Rs 2.

Q5. Is Cipla a good long-term investment?
Cipla is considered one of the stable long-term pharmaceutical plays due to its domestic leadership, export diversification, and strong chronic portfolio, though regulatory and pricing risks remain relevant.

Q6. Where can I find the latest Cipla Annual Report?
You can access the latest annual reports and financial disclosures from the Reports or Documents section available on this page.

Q7. Why is the respiratory segment important for Cipla?
The respiratory segment is one of Cipla’s strongest therapeutic categories and contributes significantly to domestic revenue, brand strength, and long-term prescription loyalty.